Roche

/Roche
­
20 05, 2016

Roche’s Cobas Mira Chemistry Analyzers for Hassle-free Operation

By |May 20th, 2016|Roche|Comments Off on Roche’s Cobas Mira Chemistry Analyzers for Hassle-free Operation

Roche’s Cobas Mira chemistry analyzers allow for the selective analysis of chemistries in either a routine or STAT mode. The units are fully programmable and ensure hassle-free operation. These systems are available refurbished in leading online lab equipment stores. This bench top analyzer includes 104 programmable test channels, 72 cuvette capacity, and an analysis interval [...]

28 09, 2015

Roche’s New ACCU-CHECK Diabetes App Provides Insulin Recommendations

By |September 28th, 2015|Roche|Comments Off on Roche’s New ACCU-CHECK Diabetes App Provides Insulin Recommendations

Physicians who treat patients needing insulin therapy to manage Type 2 diabetes find it quite difficult to teach patients how to calculate insulin bolus (short term) dosing as it is dependent on several variables. Roche has come to the rescue with its new mobile ACCU-CHEK connect diabetes management app that provides insulin dosing recommendations. When [...]

19 08, 2015

Roche Acquires GeneWEAVE to Enhance Microbiology Diagnostic Capabilities

By |August 19th, 2015|Microbiology Systems, Roche|Comments Off on Roche Acquires GeneWEAVE to Enhance Microbiology Diagnostic Capabilities

Swiss pharmaceutical giant Roche recently signed a definitive agreement to buy GeneWEAVE BioSciences, Inc. Based in Los Gatos, CA, USA, GeneWEAVE focuses on innovative, clinical microbiology systems and diagnostics solutions. This $425 million deal will provide Roche access to GeneWEAVE’s Smarticles technology and enhance its capabilities to fight drug-resistant bacteria. The groundbreaking Smarticles technology is [...]

2 06, 2015

Roche to Present New Rheumatoid Arthritis Data at EULAR 2015

By |June 2nd, 2015|Roche|Comments Off on Roche to Present New Rheumatoid Arthritis Data at EULAR 2015

Roche will present new data on rheumatoid arthritis (RA) and severe inflammatory disorders at the 16th European League Against Rheumatism Annual Congress (EULAR 2015) to be held in Rome, 10-13 June, 2015. According to the company's press release, this will include 40 data presentations across 7 autoimmune conditions as well as new results from RoACTEMRA [...]

15 04, 2015

Roche’s New Fetal DNA Test Shows Promise

By |April 15th, 2015|DNA Analyzer, Roche|Comments Off on Roche’s New Fetal DNA Test Shows Promise

Down syndrome is a chromosomal disorder caused by a gene problem that occurs before birth. Prenatal screenings are recommended for all pregnant women in U.S. to estimate the chance of the fetus having the condition. According to a study published in the New England Journal of Medicine, Roche’s new cell-free DNA analysis test for trisomy [...]

23 02, 2015

Roche’s MPDL3280A Receives Breakthrough Therapy Designation from FDA

By |February 23rd, 2015|Roche|Comments Off on Roche’s MPDL3280A Receives Breakthrough Therapy Designation from FDA

Lung cancer is the leading cause of cancer death globally. Non-small cell lung cancer (NSCLC) is the most prevalent type of the disease. Roche, the world's largest biotech company and a leader in research-focused healthcare, has announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation for its investigational cancer [...]

23 01, 2015

Roche Partnering with Meiji and Fedora to Battle Drug-resistant Bacterial Infections

By |January 23rd, 2015|Roche|Comments Off on Roche Partnering with Meiji and Fedora to Battle Drug-resistant Bacterial Infections

Roche, the world's largest biotech company and frontrunner in providing medicines in oncology, immunology, and infectious diseases has joined forces with Meiji Seika Pharma Co., Ltd. and Fedora Pharmaceuticals to fight increasing bacterial resistance to antibiotics. Under the agreement, Roche has obtained worldwide rights (except Japan) from both companies for development and commercialization of OP0595, [...]

19 01, 2015

Roche’s Blood Screening Assay Gets FDA Approval

By |January 19th, 2015|Roche|Comments Off on Roche’s Blood Screening Assay Gets FDA Approval

Roche, the leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics, has announced that the U.S. Food and Drug Administration (FDA) has approved its cobas® TaqScreen MPX Test, v2.0. This is the first nucleic acid test (NAT) to simultaneously detect and identify HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) including [...]

30 12, 2014

Roche Receives FDA Emergency Use Authorization for the LightMix® Ebola Zaire rRT-PCR Test

By |December 30th, 2014|Ebola, Roche|Comments Off on Roche Receives FDA Emergency Use Authorization for the LightMix® Ebola Zaire rRT-PCR Test

Swiss pharmaceutical giant Roche has announced that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for the LightMix® Ebola Zaire rRT-PCR Test. This test is for use on patients with signs and symptoms of Ebola Zaire virus infection in conjunction with epidemiological risk factors, such as individuals traveling from West [...]

29 08, 2014

Roche and InterMune Announce Definitive Merger

By |August 29th, 2014|Roche|Comments Off on Roche and InterMune Announce Definitive Merger

Roche has signed an agreement to purchase InterMune, a Brisbane, California-based biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. At a price of US$ 74.00 per share, the total value of the all-cash transaction is $8.3 billion. This merger will allow Roche to expand its [...]